Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Experiments designed to evaluate the effect of deletion of E2a on duration of expression using adenoviral vectors led to a series of observations regarding host responses to adenoviral vectors and reporter proteins. In studies using human alpha1-antitrypsin (hAAT) as a reporter gene, we found that the duration of expression is very brief for C3H/J and CBA/J mice but is prolonged for C57BL/6J mice, that disappearance of hAAT from the blood is correlated with the appearance of antibodies, and that immunization against hAAT can prevent appearance of the protein in the blood after administration of an adenoviral vector. Deletion of E2a in hAAT vectors did not prolong expession in C3H/J or CBA/J mice and did not shorten duration of expression in C57BL/6J mice. Using similar vectors expressing Escherichia coli beta-galactosidase (beta-Gal) in immunocompetent mice, short duration of expression with a beta-Gal reporter was remarkably different from the long expression with an identical vector expressing hAAT in C57BL/6J. In the case of vectors expressing hAAT, adenoviral sequences persisted in the liver, and inflammatory responses were minimal compared to vectors expressing beta-Gal, where adenoviral sequences disappeared from the liver concomitant with a prominent inflammatory response. The duration of expression of beta-Gal in hepatocytes was increased in transgenic mice expressing the reporter in keratinocytes, indicating that host immune responses to the reporter can limit duration of expression. Dosage studies indicated that persistence of expression of hAAT can be markedly decreased by administration of high doses of vector in a manner consistent with a nonimmune-mediated toxicity following injection. These experiments indicate that host responses to reporter genes rather than host responses to adenoviral proteins can be the primary determinant of duration of expression under many experimental conditions.
Morral
N
N
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
O'Neal
W
W
Zhou
H
H
Langston
C
C
Beaudet
A
A
D000256:Adenoviridae / Q000235:genetics*; D017502:Adenovirus E2 Proteins / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D000906:Antibodies; D004305:Dose-Response Relationship, Drug; D015967:Gene Expression Regulation, Viral; D017930:Genes, Reporter; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology*; D006801:Humans; D007114:Immunization; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011994:Recombinant Proteins / Q000097:blood / Q000235:genetics / Q000378:metabolism; D017384:Sequence Deletion; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D000515:alpha 1-Antitrypsin / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D001616:beta-Galactosidase / Q000235:genetics / Q000276:immunology / Q000378:metabolism
D017502:Adenovirus E2 Proteins; D000906:Antibodies; D011994:Recombinant Proteins; D000515:alpha 1-Antitrypsin; D001616:beta-Galactosidase